Jones Financial Companies Lllp Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Jones Financial Companies Lllp increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 7.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 237,464 shares of the biopharmaceutical company’s stock after acquiring an additional 15,554 shares during the quarter. Jones Financial Companies Lllp’s holdings in Bristol Myers Squibb were worth $10,482,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Bristol Myers Squibb by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 194,925,206 shares of the biopharmaceutical company’s stock worth $9,023,088,000 after buying an additional 3,522,202 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Bristol Myers Squibb by 1.6% in the second quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock worth $2,132,976,000 after acquiring an additional 723,459 shares during the last quarter. Norges Bank purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $1,554,154,000. Finally, Ameriprise Financial Inc. raised its stake in Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after purchasing an additional 432,158 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BMY. Citigroup reaffirmed a “neutral” rating and set a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a research note on Tuesday, January 27th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $57.43.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $57.70 on Thursday. The company’s 50-day moving average is $53.88 and its two-hundred day moving average is $48.85. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The firm has a market capitalization of $117.46 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is 85.14%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.